分子靶向治疗在结直肠癌治疗中的应用及前景

发布时间：2018-04-04 09:41

本文选题：结直肠癌　切入点：EGFR抑制剂　出处：《河北医科大学》2017年硕士论文

【摘要】：结直肠癌是最常见的恶性肿瘤之一。随着分子生物学技术飞速发展,以分子靶向治疗为主的个体化治疗在结直肠癌治疗中占据了重要的地位。近年来,作用于EGFR、VEGF和c-Met等位点的新型靶向药物不断进入临床试验,层出不穷的研究在不停地探索靶向药物联合传统化疗、免疫治疗以及不同靶向药物联合使用的疗效,以期通过高效低毒的治疗手段为患者带来最大的生存获益。本文总结了近年来结直肠癌分子靶向治疗的临床新进展,并对靶向药物的发展趋势进行了展望。
[Abstract]:Colorectal cancer is one of the most common malignant tumors.With the rapid development of molecular biology technology, individualized therapy with molecular targeted therapy plays an important role in the treatment of colorectal cancer.In recent years, new targeting drugs acting on the allelic sites of EGFR and c-Met have been continuously introduced into clinical trials, and numerous studies have been carried out to explore the efficacy of targeting drugs in combination with traditional chemotherapy, immunotherapy and combination of different targeted drugs.In order to achieve maximum survival benefits through effective and low-toxic treatment.In this review, the recent advances in molecular targeted therapy for colorectal cancer were reviewed, and the development trend of targeted drugs was prospected.
【学位授予单位】：河北医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735.34

【参考文献】